The objective of this study was to assess the oxygen cost of various intensities of steady-state cycling. VO2 (ml·min -1·kg-1) was measured at rest, during unloaded cycling (UL), 20 Watts, 50% (SS50) & 65% (SS65) of peak watts in 40 COPD patients (64 +/- 9 yrs; FEV1/FVC: 48 +/- 17 % predicted; FEV1:36 +/- 14 % predicted) and 28 age-matched healthy controls (CTRL). Despite higher VE (L·min -1) in COPD vs. CTRL (UL: 20.6 +/- 3.4 vs. 15.4 +/- 4.1; 20W: 24.3 +/- 4.5 vs. 17.8 +/- 4.2), VO2 at rest, at UL and 20W was not higher in COPD compared to CTRL. In addition, comparable slope and intercept coefficients for the VO2 vs. Watt relationship were obtained in COPD and CTRL for submaximal cycling of low to moderate intensity. (Abstract shortened by UMI.)

Chronic pulmonary disorders, marked by excessive extracellular matrix deposition (ECM) or fibrosis, are the most resistant to present clinical therapies resulting in prognoses of 50% life expectancy three years from diagnosis. Inadequacies of current treatments may be attributable to limitations in non-invasive therapeutic administration modalities. However, with the use of polyketal microparticles (PKMs), a novel drug delivery vehicle, a myriad of therapeutic schemes may be explored. Polyketals are a new polymeric family characterized by tissue biocompatibility, rapid hydrolysis, and benign degradation byproducts making it attuned for pulmonary applications. Potential treatments such as siRNA, oligo nucleotides, enzymes and other biomolecules can be encapsulated within PKMs and administered non-invasively via inhalation. For this study, we selected a model therapeutic peptide, Ac-SDKP, with established anti-fibrotic properties as the load for PKMs. For lung dysfunctions accompanied by fibrotic scarring, Ac-SDKP possesses promise in restoring the normal ECM framework. To assess PKMs viability as a pulmonary drug delivery vehicle three objectives were initially defined: 1) Synthesize particles possessing aerodynamic properties conducive for aerosolization 2) Optimization of the therapeutic load, Ac-SDKP, in PKMs to levels that will translate to clinical dosing concentrations, and 3) Determine the biocompatibility of the PKMs in the lung. Optimization of the Ac-SKDP loading within PKMs and size analysis revealed that a solid in oil in water double emulsion particle synthesis technique produced the most ideal microspheres. Based on previous reports, the loading efficiency attained, when locally dispensed, should reach clinical dosing requirements. Synthesized particles were compatible with aerosolization criteria; i.e., diameters below 3 μm and low polydispersities. In addition, we evaluated PKM tissue biocompatibility using a murine lung model. Examination of bronchoalveolar lavage fluid demonstrated only a slight inflammatory response to intratracheal particle injections of PKMs whereas PLGA, a commonly used biomaterial, elicited a significantly higher response. Histological assessment of the lungs following particle injection verified PKMs biocompatibility superiority. In conclusion, small-diameter PKMs are a suitable delivery system for pulmonary drug delivery, capable of delivering small peptide therapeutics and evading the local inflammatory response. The present work will enable expansion of therapeutic avenues capable of combating chronic lung disease.

Gene therapy is the delivery of genetic material to cells for a therapeutic effect. Retroviruses are one of the most common viral vectors used for gene therapy, especially lung gene therapy. However the lung has many physical and immunological barriers to gene transfer vectors, and currently, too few cells are genetically modified for the effective treatment of lung diseases such as cystic fibrosis. One of the main reasons for low cell transduction is the lack of commonly-used receptors for gene therapy vectors on the apical surface of polarized epithelial cells. The objective of this project was to determine how to incorporate proteins into the lentiviral lipid bilayer in order to develop a recombinant retrovirus that can efficiently deliver genes to polarized epithelial cells via their apical membranes. We analyzed the process of incorporating heterologous viral and non-viral proteins into lentiviruses and determined key factors that allowed for successful protein incorporation into the lentiviral lipid bilayer. We found that lipid rafts segregated raft proteins, and for a protein to be incorporated into virus particles, it must be colocalized with lentivirus-associated rafts. When cells were treated with the cholesterol-extracting compound, methyl-beta-cyclodextrin, previously sequestered viral and non-viral raft proteins were then colocalized and non-viral proteins were incorporated into lentiviruses. We also created a lentivirus pseudotyped with envelope proteins from human parainfluenza type 3 (HPIV3), which naturally targets polarized epithelial cells of the lung. Lentiviruses were able to incorporate HPIV3 glycoproteins, hemagglutinin-neuraminidase (HN) and fusion (F), and were able to transduce polarized cells in a manner consistent with lentiviral-mediated transduction via sialated receptors for HPIV3, however titers were too low for clinical use. We increased protein expression of HN and found that while expression, envelope incorporation, and titer increased, lentiviruses still incorporated too few envelope proteins for efficient transduction. We determined low envelope incorporation rates were due to lack of interactions with Gag, and increasing active and passive interactions with Gag enhanced HN and F incorporation into lentiviruses. Overall, this research is significant because it provides insight into viral assembly and protein incorporation for the generation of pseudotyped lentiviruses for human gene transfer.

[Truncated abstract] Urinary desmosines have been proposed as a biomarker for inflammatory lung damage. Desmosine, a breakdown product of elastin, is an effective marker of the degradation of elastin and has been studied in many disease scenarios where there is acute and chronic lung inflammation. Lung matrix degradation has been proven in vitro and in vivo with many experiments showing that the excess proteases degrades lung matrix. The secretion of proteases by neutrophils is an innate response of the body to the invasion by micro organisms and when secreted in excess, the protective anti-protease mechanism is swamped. Chronic inflammation and persistent infection eventually leads to bronchiectasis and respiratory failure. Urinary desmosine has been shown to be elevated in respiratory conditions with acute and chronic inflammation . . . Urinary desmosine levels in a large cohort of healthy children have been established using this method and predictive Z-score formulae have been developed to use in children with lung disease. Exploration of these scores in children with CF have shown that the levels of urinary desmosine appear to be sensitive to the clinical setting, where high urinary desmosine levels were present during exacerbation and significantly reduced when treated for infection with antibiotic therapy and physiotherapy. The study of young children under the age of seven was undertaken to determine if the urinary desmosine levels could indicate when lung damage was occurring and to determine what mechanisms might be involved. Since there appeared to be no apparent relationship between elevated desmosines and proteases in the lung in young children with CF, further studies are required to define the mechanisms behind increased elastin metabolism in those children.

Orientador: Roberto Calderon Gonçalves / Banca: Simone Biagio Chiacchio / Banca: Fernando José Benesi / Resumo: Os ovinos são muito susceptíveis às doenças pulmonares, sendo a broncopneumonia mais frequente e responsável por desencadear intensa resposta inflamatória, sistêmica e local, principalmente neutrofílica. O objetivo deste estudo foi analisar a resposta inflamatória sistêmica e pulmonar de ovinos portadores de broncopneumonia moderada e grave e as atividades neutrofílicas através dos testes estimulado (NBT-E) ou não (NBT-NE), com Tetrazólio Nitroazul, no sangue periférico e no lavado traqueobrônquico. Para isso, por exame clínico, 50 ovinos foram selecionados e subdivididos em três grupos: G1 - animais sadios (n=19); G2 - portadores de broncopneumonia moderada (n=21); e G3 - portadores de broncopneumonia grave (n=10). A resposta inflamatória sistêmica foi avaliada pela interpretação do exame físico, leucograma e fibrinogênio plasmático. A resposta inflamatória local, por sua vez, pela associação das alterações respiratórias ao exame físico específico e à celularidade do lavado traqueobrônquico (LTB). A atividade dos neutrófilos sanguíneos dos grupos G1 e G2 foi percentualmente semelhante e a daqueles do LTB nula. O G3 apresentou diminuição da porcentagem de neutrófilos sanguíneos ativados e atividade de NBT significativa dessas células no LTB. Nestas condições experimentais, os resultados demonstraram que o exame clínico minucioso e a associação dos sinais clínicos são fidedignos para a graduação dos estágios da broncopneumonia; a gravidade das respostas inflamatórias, sistêmica e local, é dependente do grau de comprometimento pulmonar e há tendência à leucocitose neutrofílica e ao aumento do número de células nucleadas no LTB conforme a gravidade da doença; há redução do número de neutrófilos ativos circulantes e presença destes no LTB nas broncopneumonias graves / Abstract: Ovine are highly susceptible to lung diseases, being bronchopneumonia the most frequent and responsible for triggering intense inflammatory response, systemic and local, mainly neutrophilic. The aim of this study was analyze lung and systemic inflammation of moderate and severe bronchopneumonia affected ovine and the neutrophilic activity through stimulated (S-NBT) and not stimulated (NS-NBT) assays with Nitroblue Tetrazolium, on peripheral blood and on tracheobronchial lavage (TBL). For that, 50 animals were selected and divided based on clinical examination into three groups: G1 - healthy animals (n=19), G2 - moderate bronchopneumonia (n=21), and G3 - severe bronchopneumonia (n=10). The systemic inflammation was evaluated by the interpretation of physics parameters, white blood cells (WBC) counts and plasma fibrinogen. The local inflammatory response, in turn, by the association of respiratory abnormalities on physical examination and the TBL cellularity. The systemic neutrophils activity from G1 and G2 were similar, and the lung neutrophils activity was null. The G3 showed a reduction of the activated systemic neutrophils rate, and expressive activity of these cells on the TBL. On these experimental conditions the results showed that a detailed clinical examination associated with the clinical signs is a reliable method for the graduation of the bronchopneumonia severity; the gravity of the local and systemic inflammation relies on the lung commitment degree and there is a tendency to neutrophilic leukocytosis and increase of the nucleated cells number on the TBL, associated with the illness severity; there is a reduction of active circulating neutrophils and its presence on the TBL when the animal is stricken by severe bronchopneumonia / Mestre

Orientador: Irma Godoy / Banca: Suzana Erico Tanni / Banca: Hugo Hyung Bok Yoo / Banca: Oliver Augusto Nascimento / Banca: Marcia Maria Faganello / Resumo: Estudos mostram que os valores médios da Interleucina 6 (IL-6) e Proteína CReativa (PCR) não mudam significativamente em pacientes com DPOC no período de um ano. No entanto, o acompanhamento de longo prazo desses mediadores não está estabelecido. Portanto, o objetivo do atual estudo é verificar a evolução dos marcadores inflamatórios sistêmicos de pacientes com DPOC após três anos e verificar a associação entre eles e os demais marcadores da doença. Uma coorte de 77 pacientes com DPOC estável foi avaliada no momento basal e 53 (VEF1=56±21%) foram incluídos no estudo. Nós avaliamos IL-6, PCR, distância percorrida em seis minutos (DP6) e índice de massa corporal (IMC) no momento basal e após três anos. A concentração plasmática de IL-6 foi avaliada por meio de ensaios imunoenzimáticos (ELISA) ultrassensíveis e a PCR foi obtida por meio de imunonefelometria com uso de kits ultrassensíveis. Os valores da IL-6 aumentaram significativamente após três anos em comparação ao momento basal [0,8 (0,5-1,3) vs 2,4 (1,3-4,4) pg/ml, p <0,001] e foram associados com piora da DP6. Os resultados da análise de regressão de Cox mostraram que os valores aumentados de IL-6 no momento basal foram associados com a mortalidade [Hazard Ratio (95% CI)=2,68 (0,13; 1,84); p=0,02]. Os valores médios da PCR não apresentaram alteração significativa [5 (1,6-7,9) vs 4,7 (1,7-10) mg/ L, p=0,84]; embora, onze pacientes (21%) apresentaram aumento >3 mg/L da PCR no período de três anos. O processo inflamatório sistêmico, avaliado pela IL-6, parece ser persistente e progressivo e associado com mortalidade e piora da performance física em pacientes com DPOC / Abstract: Past studies have shown that mean values of Interleukin-6 (IL-6) and Creactive protein (CRP) do not change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD patients and to test the association between these inflammatory mediators and disease outcome markers. A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV1, 56% predicted) were included in the prospective study. We evaluated IL-6, CRP, six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity particle-enhanced immunonephelometry. IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4) pg/ml; p<0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at baseline was associated with mortality [Hazard Ratio (95% CI)=2.68 (0.13, 1.84); p=0.02]. CRP mean values did not change [5 (1.6- 7.9) vs 4.7 (1.7-10) pg/L; p=0.84], although eleven patients (21%) presented with changes >3 mg/L in CRP after 3 years. The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and associated with mortality and worse physical performance in COPD patients / Doutor

Orientador: Fernando Rogério Pavan / Banca: Jean Leandro dos Santos / Banca: Flávio da Silva Emery / Resumo: A Tuberculose (TB) é uma doença infectocontagiosa que possui como agente etiológico o Mycobacterium tuberculosis e que levou ao óbito, em 2016, 1,3 milhões de pessoas ao redor do mundo. Seu tratamento, recomendado pela Organização Mundial da Saúde, constitui-se da utilização de quatro antimicrobianos por, no mínimo, seis meses. Este esquema de tratamento apresenta variados efeitos adversos que levam o paciente a abandonar a terapia logo no início do desaparecimento dos sintomas, levando ao surgimento de cepas resistentes. As infecções provocadas por cepas resistentes aos fármacos vêm aumentando com o passar dos anos, o que se tornou um dos maiores problemas para o controle da doença. Dessa forma, é essencial a busca por novos candidatos a fármacos, com o objetivo de diminuir o tempo de tratamento e a disseminação de cepas resistentes. Em um estudo prévio do grupo, foram sintetizados compostos da classe das hidrazonas que mostraram interessante atividade contra o M. tuberculosis. Nesse trabalho, aprofundamos o estudo de quatro dessas moléculas, numeradas como 14, 15, 16 e 18. Os resultados obtidos indicaram a molécula 14 (C16H15O2N3) como a mais promissora, apresentando o menor valor de concentração inibitória mínima (CIM90) de 0,35 g/mL frente a cepa padrão sensível aos antibióticos em estado ativo de replicação e 1,78 g/mL quando em estado não-replicante. Além disso, apresentou um perfil bactericida e atividade intramacrofágica. Frente às células eucarióticas, a hidrazona ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. In 2016, was the cause of death of 1.3 million people around the world. Its treatment, recommended by the World Health Organization, consists of the use of four antibiotics for at least six months. This treatment regimen has several adverse effects that lead the patient to abandon the therapy at the beginning of the disappearance of the symptoms, which leads to the emergence of resistant strains. Infections caused by drug-resistant strains have been increasing over the years, which has become one of the major problems in controlling the disease. Because of that, the search for new compounds occurs with the objective of reducing the time of treatment and inhibiting the growth of resistant strains. In a previous study of the group, compounds of the class of hydrazones that showed interesting activity against M. tuberculosis were synthesized. In this work, we investigated four of these molecules, numbered as 14, 15, 16 and 18. The results indicated that hydrazona 14 (C16H15O2N3) was the most promising molecule because it presented the lowest minimum inhibitory concentration (MIC90) of 0.35 g/mL against H37Rv strain, in active replication state and 1.78 g/mL when in non-replicating state. In addition, it presented a bactericidal and intramacrophagic activity. In the cytotoxicity assays, hydrazone 14 presented no cytotoxicity (IC50) in all treatment times and high selectivity index (IS), as well as presenting a narrow spectrum of activity and, therefore, presents itself as the most promising molecule. Therefore, this hydrazone was investigated about its mechanism of action. Therefore, it was used techniques that could demonstrate the inhibition of the synthesis of mycolic acids presents... (Complete abstract click electronic access below) / Mestre

Made available in DSpace on 2014-06-11T19:32:12Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-01-31Bitstream added on 2014-06-13T19:21:36Z : No. of bitstreams: 1 ferrari_r_dr_botfm.pdf: 683564 bytes, checksum: 4f22fe73c82611851ed24de3858cb5e6 (MD5) / Estudos mostram que os valores médios da Interleucina 6 (IL-6) e Proteína CReativa (PCR) não mudam significativamente em pacientes com DPOC no período de um ano. No entanto, o acompanhamento de longo prazo desses mediadores não está estabelecido. Portanto, o objetivo do atual estudo é verificar a evolução dos marcadores inflamatórios sistêmicos de pacientes com DPOC após três anos e verificar a associação entre eles e os demais marcadores da doença. Uma coorte de 77 pacientes com DPOC estável foi avaliada no momento basal e 53 (VEF1=56±21%) foram incluídos no estudo. Nós avaliamos IL-6, PCR, distância percorrida em seis minutos (DP6) e índice de massa corporal (IMC) no momento basal e após três anos. A concentração plasmática de IL-6 foi avaliada por meio de ensaios imunoenzimáticos (ELISA) ultrassensíveis e a PCR foi obtida por meio de imunonefelometria com uso de kits ultrassensíveis. Os valores da IL-6 aumentaram significativamente após três anos em comparação ao momento basal [0,8 (0,5-1,3) vs 2,4 (1,3-4,4) pg/ml, p <0,001] e foram associados com piora da DP6. Os resultados da análise de regressão de Cox mostraram que os valores aumentados de IL-6 no momento basal foram associados com a mortalidade [Hazard Ratio (95% CI)=2,68 (0,13; 1,84); p=0,02]. Os valores médios da PCR não apresentaram alteração significativa [5 (1,6-7,9) vs 4,7 (1,7-10) mg/ L, p=0,84]; embora, onze pacientes (21%) apresentaram aumento >3 mg/L da PCR no período de três anos. O processo inflamatório sistêmico, avaliado pela IL-6, parece ser persistente e progressivo e associado com mortalidade e piora da performance física em pacientes com DPOC / Past studies have shown that mean values of Interleukin-6 (IL-6) and Creactive protein (CRP) do not change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD patients and to test the association between these inflammatory mediators and disease outcome markers. A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV1, 56% predicted) were included in the prospective study. We evaluated IL-6, CRP, six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity particle-enhanced immunonephelometry. IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4) pg/ml; p<0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at baseline was associated with mortality [Hazard Ratio (95% CI)=2.68 (0.13, 1.84); p=0.02]. CRP mean values did not change [5 (1.6- 7.9) vs 4.7 (1.7-10) pg/L; p=0.84], although eleven patients (21%) presented with changes >3 mg/L in CRP after 3 years. The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and associated with mortality and worse physical performance in COPD patients

Made available in DSpace on 2014-06-11T19:35:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-11-27Bitstream added on 2014-06-13T20:06:50Z : No. of bitstreams: 1 000741348.pdf: 860328 bytes, checksum: 0387fdd2294fcddfbdafe18aaa5bc76b (MD5) / De acordo com a Organização Mundial da Saúde (OMS), a Doença Pulmonar Obstrutiva Crônica (DPOC) é uma das doenças crônicas mais prevalentes, que afeta 210 milhões de pessoas em todo o mundo, sendo a quinta causa mais comum de morte e a décima doença mais onerosa. Estudo realizado em países latino-americanos estimou que a prevalência da DPOC é maior que 10% entre adultos com 40 anos ou mais, e a mortalidade associada a essa doença deve aumentar e será a terceira causa de morte no ano de 2030. Dados do DATASUS mostram que, no Brasil, a DPOC foi responsável por 107.154 admissões no SUS em 2012, com permanência média de internação de seis dias. O número de óbitos, em 2012, por DPOC foi em torno de 7.801, resultando em uma taxa de mortalidade de 6,14%. O custo estimado por paciente por ano com DPOC é de R$ 757,00, sendo que o valor total gasto no ano de 2012 foi de R$ 96.222.080,03. Diretrizes da prática clínica baseadas em evidências para o diagnóstico e gerenciamento da DPOC têm sido desenvolvidas e publicadas, inclusive no Brasil. Existe concordância entre as diretrizes nacionais e internacionais com relação à eficácia da cessação do tabagismo, da reabilitação pulmonar, da vacinação contra a gripe, do uso de medicamentos e da oxigenoterapia domiciliar prolongada para pacientes com hipoxêmia. Entretanto, existem dados que mostram lacunas no gerenciamento da DPOC. Portanto, novos estudos são necessários para melhor compreender os aspectos que possam contribuir para uma melhor gestão dessa doença tão altamente prevalente. Verificar se as questões fundamentais para estabelecer o diagnóstico e avaliar a gravidade da doença estão presentes nos dados clínicos dos pacientes internados com diagnóstico de Doença Pulmonar Obstrutiva Crônica em um Hospital Geral, no período de Abril de 2011 a Março de 2012. Estudo quantitativo do tipo documental retrospectivo. Foram... / According to the World Health Organization (WHO), Chronic Obstructive Pulmonary Disease (COPD) is one of the most prevalent chronic diseases, affecting 210 million individuals worldwide and is the 5th most common cause of death among chronic diseases and 10th most costly disease. A Latin-American study has estimated the prevalence of COPD as more than 10% in adults with more than 40 years, and states that mortality rates will rise and it will become the third most common cause of death in 2030. According to DATASUS, COPD was responsible for 107.154 public hospital admissions in 2012, with a median stay of 6 days. In the same year, COPD was responsible for 7.801 deaths with a mortality rate of 6,14%. In one year, it is estimated that COPD costs R$ 757,00 per patient, and costs in 2012 resulted in R$ 96.22.080,03. Evidence based clinical guidelines are being developed and published also in Brazil. National and international guidelines agree on the efficacy of tobacco use cessation, pulmonary rehabilitation, influenza vaccination, use of medication and prolonged domiciliary oxygen therapy for patients with hipoxemia. However there are some gaps in COPD management, and new studies are necessary to better understand the factors that may improve the management of such a prevalent disease. Verify if fundamental questions to establish and evaluate severity of the disease are present in clinical data from patients admitted because of COPD in a brazilian general hospital between april 2011 and march 2012. Retrospective quantitative study. 236 patients admitted in the Bauru State Hospital with COPD diagnosis were evaluated, in 402 admissions. It has been observed that 50% of them were male, the majority of them between 66-90 years old with a median age of 68 + 11,2 years and 86,9% of the patients had less then 5 years of education. Hospital stay was 13,4 days + 17,1 day with a median of 8 days. 57,1% of the ...

Made available in DSpace on 2015-08-20T17:09:46Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-02-24. Added 1 bitstream(s) on 2015-08-20T17:26:26Z : No. of bitstreams: 1 000841364.pdf: 1752368 bytes, checksum: 554dce65db90eaa82a7014120fd56047 (MD5) / Introdução: Exacerbação aguda (EA) é uma importante causa de perda de funções em pacientes que sofrem de doença pulmonar obstrutiva crônica (DPOC). Afeta negativamente a qualidade de vida, a função pulmonar, a fraqueza muscular, a utilização dos recursos da saúde e a sobrevida. Entretanto, o exercício físico realizado durante a exacerbação pode melhorar a qualidade de vida e a capacidade física do paciente. Nesse contexto, o presente estudo visa avaliar a influência da realização do exercício físico em pacientes hospitalizado por exacerbação da DPOC (EADPOC). Objetivo: O presente estudo visa avaliar os efeitos do exercício fisico aeróbio de curta duração nos pacientes hospitalizados por exacerbação aguda de DPOC no escore da dispneia, na qualidade de vida e na capacidade física. Pacientes e Métodos: Vinte e dois pacientes foram randomizados em dois grupos, o grupo controle que recebeu o tratamento clínico padrão e o grupo de intervenção que realizou o treinamento de exercício físico juntamente com os cuidados clínicos. Os pacientes foram submetidos às seguintes avaliações após 48 horas da hospitalização e após um mês da alta: espirometria, avaliação nutricional, distância percorrida no teste de caminhada de seis minutos (DP6), qualidade de vida, ansiedade e depressão, índice de BODE e intensidade de dispneia. O programa de exercício físico foi composto por treinamento aeróbio em esteira ergométrica, duas vezes ao dia, por 15 minutos cada sessão até o período da alta hospitalar. Resultados: O domínio impacto e o escore total da qualidade de vida apresentaram maior incremento no grupo intervenção em relação ao grupo controle (p < 0,001) quando comparado os momentos. Houve melhora de ambos os grupos após um mês de alta hospitalar no domínio atividade quando comparado ao momento basal, mas sem diferença entre os grupos. Além disso, apenas o grupo de intervenção apresentou... / Introduction: Acute Exacerbation (AE) is an important cause of impairment of function in chronic obstructive pulmonary disease (COPD) patients. Negatively affects the quality of life, lung function, muscle weakness, the use of health resources and survival. However, physical exercise performed during the exacerbation can improve the quality of life and the physical capacity of the patient. In this context, this study aims to evaluate the influence of aerobic exercise in hospitalized COPD patients with exacerbation (AECOPD). Objective: To evaluate the effects of short duration aerobic exercise in AECOPD on dyspnea score, quality of life and exercise capacity. Patients and Methods: Twenty-two patients were randomized in two groups; the control group received standard medical treatment and the intervention group that performed aerobic exercise training. All patients performed spirometry, nutritional assessment, distance covered on the six-minute walk test (6MWD), quality of life (Saint George Respiratory Questionnaire- SGRQ), anxiety and depression ( The Hospital Anxiety and Depression Scale), BODE index and intensity of dyspnea (Baseline Dyspnea Index and Modified Medical Research Council Score) after 48 hours of hospitalization and after one month of discharge. The exercise program consisted of aerobic training on a treadmill twice a day for 15 minutes until to the discharge. Results: The impact domain and the total score of quality of life showed a higher increase in the intervention group compared to the control group (p<0.001) when compared to the moments. Both groups showed improvement in the activity domain of SGRQ after one month of hospital discharge, but they did not show difference between groups. Furthermore, only the intervention group showed significant improvement in the symptom domain of SGRQ (p<0.001) and baseline dyspnea index (p=0.006) after one month. 6MWD and BODE did not show difference between ...